Epigenomics

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Retrieved on: 
Tuesday, April 9, 2024
Epigenomics, EGFR, NSCLC, Patient, DNA, Messenger, Lung cancer, Therapy, MYC

Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller

Key Points: 
  • Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller
    CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10.
  • The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate, OTX-2002.
  • “We’re excited to share these preclinical data at this year’s AACR Annual Meeting, which continue to validate Omega’s platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “These results further underscore the tremendous potential for a MYC-directed epigenomic controller as a novel orthogonal treatment strategy for non-small cell lung cancer as a monotherapy and in combination with existing therapies.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Pharmaceutical, Oncology, Data Management, Consumer, Technology, Artificial Intelligence, Health Technology, Data Analytics, Women, Biotechnology, Health, Helmy Eltoukhy, Patient, Neoplasm, Research, AACR, Epigenomics, Breast cancer, MRD

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
  • Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction.
  • Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen.
  • “We look forward to sharing new data at AACR, in particular studies demonstrating the potential for epigenomic analysis using the Guardant Infinity platform to advance cancer research,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

Retrieved on: 
Thursday, March 14, 2024
Other Health, Software, General Health, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Other Technology, Health, Cardio, Genomics, Organization, Cardiovascular disease, ACI, Entrepreneurship, Patient, Artificial intelligence, Medicine, CHD, American College, Heart, Epigenomics, Moyamoya disease, ACC, Pharmaceutical industry

Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."

Key Points: 
  • Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."
  • All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.
  • Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights.
  • "Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, can potentially revolutionize how healthcare professionals approach cardiovascular disease prevention, detection and management.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024
Shift, Therapy, Epigenomics, Central nervous system, Alzheimer's disease, KCNK10, Astrocyte, Date, Conference, Mechanism, CNS, Gene, DSM-IV codes

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Thursday, February 15, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, AI, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

EQS-News: Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Retrieved on: 
Thursday, February 15, 2024
Supervisory board, Investment, Supervision, Epigenomics AG, Epigenomics, AG, News, ECX, Annual, WSB, MBB, Security (finance)

Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.

Key Points: 
  • Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.
  • Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024.
  • For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024.
  • Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Tuesday, February 13, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Sigma-Aldrich, Epigenomics, Cornell University, MAI, Bruker, Abraxis BioScience, Principal, Biotechnology, Research, General partnership, Viridos (company), NGS, St. Louis, Biophysics, Protein engineering, Doctor of Philosophy, Gen-Probe, Synthetic biology, Gene editing, Cell biology, Dicarboxylic acid, Gene, Oligonucleotide, Thermo Fisher Scientific, Genomics, Horizon Discovery, CTAB, DNA, Fine chemical

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.